REGENERON PHARMACEUTICALS (REGN:NASDAQ)
$618.4 3.67 (0.597%)
Analysed REGENERON PHARMACEUTICALS (REGN:NASDAQ) News Sources
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
05-06-2026
yahoo.com
Regeneron’s (REGN) Antibody Therapy Gains WHO Support During Ebola Outbreak
09-06-2026
yahoo.com
Parabilis sets a record with a $670M biotech IPO
10-06-2026
biopharmadive.com
Parabilis Medicines raises record $670 million in biotech IPO
10-06-2026
qz.com
Parabilis Raises Nearly $745 Million As IPO Demand Surges
10-06-2026
yahoo.com
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
11-06-2026
biopharmadive.com
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now?
11-06-2026
yahoo.com
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
12-06-2026
yahoo.com
Regeneron Broadens Pipeline With Ebola Antibody Trials And Bispecific Cancer Bets
13-06-2026
yahoo.com
3 Profitable Stocks We Think Twice About
17-06-2026
yahoo.com
What is the current price of REGENERON PHARMACEUTICALS (REGN:NASDAQ)?
The current price of REGENERON PHARMACEUTICALS (REGN:NASDAQ) is $618.4.
REGENERON PHARMACEUTICALS (REGN:NASDAQ) absolute price change since previous trading day?
The absolute price change of REGENERON PHARMACEUTICALS (REGN:NASDAQ) since the previous trading day is $3.67.
REGENERON PHARMACEUTICALS (REGN:NASDAQ) percentage price change since previous trading day?
The percentage price change of REGENERON PHARMACEUTICALS (REGN:NASDAQ) since the previous trading day is 0.597%.
What is the most recent average sentiment score for REGENERON PHARMACEUTICALS (REGN:NASDAQ)?
The most recent average sentiment score for REGENERON PHARMACEUTICALS (REGN:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for REGENERON PHARMACEUTICALS (REGN:NASDAQ)?
The most recent sentiment for REGENERON PHARMACEUTICALS (REGN:NASDAQ) is .
SEC-8K** Filing Available For REGENERON PHARMACEUTICALS (REGN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.